Clinical trials: Alcoholic Liver Disease
Atherosclerosis, Cardiovascular Risk Factor
Early Vascular Ageing in the YOUth
This is a single-center observational study on adolescents to determine predictors of the early steps of the formation of atherosclerosis and to quantify their influence on Intima-Media-Thickness of the carotid artery and the…
- Conditions
- Atherosclerosis, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Pathology
- Trial name
- EVA4YOU (NCT04598685)
- Where
- Austria
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Non-alcoholic Fatty Liver Disease
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device…
- Trial name
- BEN (NCT02950610)
- Testing
- Breath analysis - electronic signature "Breath-print"
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Non Alcoholic Steatohepatitis
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who…
- Trial name
- NCT02721264
- Testing
- Fecal Microbiota Transplant, Standard Medical Treatment
- Where
- India
- Volunteers
- 112 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Non-Alcoholic Fatty Liver Disease
Measuring Fatty Liver With Ultrasound and MRS in Children With Overweight or Obesity
Obesity is associated with a variety of comorbidities, amongst which non-alcoholic fatty liver disease (NAFLD). A recent meta-analysis has shown that the prevalence of NAFLD in obese pediatric populations is around 35%, compared…
- Trial name
- NCT03787108
- Testing
- Magnetic resonance spectroscopy measurement
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- Maastricht University Medical Center
Liver Diseases
Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver…
- Trial name
- NCT03172650
- Testing
- glomerular filtration rate
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%.
- Conditions
- Non-alcoholic Fatty Liver Disease, Liver Fibrosis, Liver Injury
- Trial name
- NCT06244550
- Testing
- Ganwei, Metformin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei City Hospital
Psoriasis, Nonalcoholic Fatty Liver Disease
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
Main objectives 1. Establish the association of psoriasis and the presence of NAFLD in the patients with psoriasis attending dermatologic clinic center. Secondary objective 1.
- Trial name
- NCT00930384
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- George Washington University
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
NAFLD (Nonalcoholic Fatty Liver Disease)
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
- Trial name
- NCT06932289
- Testing
- Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Greater Los Angeles Healthcare System
NAFLD - Nonalcoholic Fatty Liver Disease
Losartan for the Treatment of Pediatric NAFLD
A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
- Trial name
- STOP-NAFLD (NCT03467217)
- Testing
- Losartan potassium
- Where
- 10 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
- Trial name
- NCT03073343
- Testing
- Betaine (trimethyglycine)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern California Institute for Research and Education
Non-Alcoholic Fatty Liver Disease, Hepatitis B
A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction
- Trial name
- NCT02985450
- Testing
- Engerix-B
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University of Calgary
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Alcoholic Liver Disease
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
This is a research study of a text-messaging intervention to reduce alcohol relapse risk in pre-transplant liver transplantation patients.
- Trial name
- NCT03402256
- Testing
- Text Message
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
NAFLD Primary Care
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Type2 Diabetes, Metabolic Syndrome
- Trial name
- NCT04918732
- Testing
- FibroScan
- Where
- Netherlands
- Volunteers
- 1,470 people
- Sponsor
- Maastricht University